This is a working overview of bremelanotide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-01-10. Anything still debated is marked as such rather than presented as settled.
How receptor activation translates into a change in desire is not established in detail. Proposed steps include modulation of dopaminergic signalling in reward circuits and downstream effects on autonomic tone. Human data consist mainly of clinical trials measuring self-reported outcomes rather than direct measurements of brain activity or transmitter release. The transient rise in blood pressure sometimes observed after administration is likewise reported consistently but explained only partly by known melanocortin pathways.
Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
| Property | Value | Notes |
|---|---|---|
| Primary receptor target | MC4R agonist | Subtype most often linked to behavioural effects |
| Other reported targets | MC1R, MC3R, MC5R | Activity is not selective for a single subtype |
| Endogenous ligand class | Melanocortin peptides | Alpha-MSH and ACTH act on the same family |
| Peptide architecture | Cyclic heptapeptide | Lactam bridge between the aspartate and lysine residues |
| Central action | Inferred from animal models | Not directly measured in the human brain |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
The Financial Times wrote that the strikes were intended to pressure members of the Venezuelan government into resigning or arranging a handover of power by demonstrating the US military's capability to capture or kill them through targeted strikes. According to The New York Times, "specialists in the laws of war and executive power" stated that Trump had "used the military in a way that had no clear legal precedent or basis". In an interview with Vanity Fair magazine, Susie Wiles, Trump's White House Chief of Staff, told journalist Chris Whipple that Trump would "keep on blowing boats up until Maduro cries uncle." Whipple himself believed the terminology spoke to the possibility of Trump wanting to see regime change, and Wiles described the Vanity Fair article as "a hit piece".
== Current application of LED light therapy == Red light therapy, utilising red LED lights, originated from techniques intended to enhance plant growth in space and aid in astronauts' wound healing. Primarily used in dermatology, it enhances skin conditions by stimulating mitochondria, thereby increasing collagen production and blood circulation while reducing inflammation. Additionally, it plays a crucial role in photodynamic therapy, where it combines with photosensitive drugs to target and destroy cancerous cells through a light-induced chemical reaction. Blue light therapy is also a common LED light therapy to treat acne, skin cancer, and depression. While blue light therapy has similar mechanisms for skin enhancement as red light therapy, its usage for photodynamic therapies in treating cancer are slightly different. Blue light therapy stimulates immune system defences, destroys blood vessels that help cancer cells grow, and causes cell death by reacting with oxygen. It also prevents skin cancer and metastasis by removing precancerous and cancerous skin lesions. Application of red and blue LED light for photodynamic treatments are generally safe and can be used to treat different cancers. However, they may differ in the efficiency and response. For instance, In the treatment of Gorlin syndrome, a genetic disorder predisposed to cancer, studies have shown that blue light therapy achieves a higher tumor clearance rate and induces less pain than red light therapy.
The COVID-19 pandemic in North Korea was part of a global pandemic of coronavirus disease 2019 (COVID-19), a novel infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). North Korea confirmed its first case on 8 May 2022. North Korea is a secretive and diplomatically isolated country in East Asia. Its weak healthcare system and impoverished population led to concerns over the country's vulnerability to an outbreak, though its cold chain vaccination program had proven capable in prior pandemics. With a totalitarian political system, little information on the pandemic's impacts on North Korea has been available to international observers. In January 2020, the North Korean government began taking extensive measures to protect itself from the initial COVID-19 outbreak, including the establishment of quarantine facilities, and strict travel restrictions. In March and April 2020, the Asia Times and 38 North reported that these measures seemed largely successful. Before May 2022, the government of North Korea had not reported any confirmed cases of COVID-19, although some foreign analysts believed that the virus had spread there by March 2020. Daily NK, a South Korean dissident-run news website, said that about 180 soldiers had possibly died from COVID-19 symptoms in January and February 2020. In July 2020, a single suspected case in Kaesong prompted a three-week lockdown. By 2021, there were increasing reports that the isolation imposed to avoid the pandemic was having a major impact on the economy.
Executive Order 13771 of January 30, 2017 (Reducing Regulation and Controlling Regulatory Costs); Executive Order 13777 of February 24, 2017 (Enforcing the Regulatory Reform Agenda); Executive Order 13875 of June 14, 2019 (Evaluating and Improving the Utility of Federal Advisory Committees); Executive Order 13891 of October 9, 2019 (Promoting the Rule of Law Through Improved Agency Guidance Documents); Executive Order 13892 of October 9, 2019 (Promoting the Rule of Law Through Transparency and Fairness in Civil Administrative Enforcement and Adjudication); Executive Order 13893 of October 10, 2019 (Increasing Government Accountability for Administrative Actions by Reinvigorating Administrative PAYGO).
== Adverse effects == Adverse drug reactions (ADRs) are rare when lidocaine is used as a local anesthetic and is administered correctly. Most ADRs associated with lidocaine for anesthesia relate to administration technique (resulting in systemic exposure) or pharmacological effects of anesthesia, and allergic reactions only rarely occur. Systemic exposure to excessive quantities of lidocaine mainly results in central nervous system (CNS) and cardiovascular effects – CNS effects usually occur at lower blood plasma concentrations and additional cardiovascular effects present at higher concentrations, though cardiovascular collapse may also occur with low concentrations. ADRs by individual organ systems are:
Sources: en.wikipedia.org
A submarine sandwich, commonly known as a sub, is a type of American cold or hot sandwich made from a submarine roll (an elongated bread roll) that is split lengthwise and filled with meats, cheeses, vegetables, and condiments. Although "submarine" or just "sub" is the general term for both the bread roll and sandwiches made with it in both the US and other English speaking nations, there are many local nicknames, especially in the northeastern United States, such as hoagie (Philadelphia English and Western Pennsylvania English), hero (New York City English), Italian (Maine English), grinder (New England English, Fulton County, NY), wedge (Westchester, NY) or spuckie (Boston English).
During World War II, wartime manufacturing expanded urban employment for black job seekers who were historically underrepresented in Detroit's labor market as labor policies sanctioned hiring discrimination. Despite the expansion of employment available to black Detroiters, racial integration within the workplace was met with fierce opposition from Blue-collar white employees. For these white Detroiters, black employment harbored intense housing competition within Detroit's overcrowded neighborhoods in addition to crumbling the economic stability of Detroit's white middle class. Therefore, as racial integration within the workplace alluded to racially fluid neighborhoods, the white middle class engaged in residential segregation by using discriminatory behavior and policy to regulate black residential agency and accessibility to homeownership. Transitioning into the postwar period, the economic hardships of manufacturing industries, stemming from suburbanization, along with overpriced rental housing, forced urban black communities to fall on hard times, devolving into decrepit remnants of Detroit's industrial surgency and booming wartime economy. The mass migration of hopeful blacks from the Jim Crow-perpetuated racism and segregation of the South into Northern neighborhoods coupled with sluggish housing construction flooded Detroit with overpopulation, limited funding, and residential mistreatment. Black families faced large down payments, high-interest land contracts, and high maintenance costs of living facilities.
=== Benzofurans === Benzofurans are similar in structure to MD(M)A but differ in that the methylenedioxy groups have been modified, removing one of the two oxygens in the methylenedioxy ring to render a benzofuran ring.
== External links == molecularfarming.com Official site Molecular Farming – Plant Bioreactors Moss bioreactors do not smell (Interview with Ralf Reski) Molecular Pharming – pharmaceuticals with the help of GM plants Pharming for Farmaceuticals "Pharming the Field: A Look at the Benefits and Risks of Bioengineering Plants to Produce Pharmaceuticals". The Pew Charitable Trusts. July 18, 2002. USDA-APHIS Biotechnology Regulatory Services[link removed] EPA Biotechnology page FDA Biotechnology page Archived 2009-05-17 at the Wayback Machine Homepage of the Coordinated Framework for Regulation of Biotechnology Draft Guidance for APHIS Permits for Field Testing or Movement of Organisms with Pharmaceutical or Industrial Intent PlantPharma.org Online Community Archived 2021-04-18 at the Wayback Machine National Science Foundation Pharma-Planta Consortium Biotechnology Industry Organization Society for Moleculture, a non-for-profit organisation for plant- factories, Québec, Canada
Sources: en.wikipedia.org
Bremelanotide binds several melanocortin receptors, and MC4R is the subtype most often cited as responsible for its behavioural effects. Activity at MC1R, MC3R and MC5R is also reported. Selectivity is therefore described as limited rather than precise.
It is not classified as a vasodilator, and its proposed site of action is the central nervous system rather than peripheral vessels. Some trial participants show small transient blood pressure changes. Whether those changes arise centrally or through another route remains an open question.
Most evidence comes from animal models and from indirect human outcomes such as self-reported desire. Direct measurements of receptor occupancy or signalling in the human brain are not available. Published reviews therefore present a plausible pathway rather than a confirmed sequence of events.
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.